EUCTR2013-004810-16-NL进行中（未招募）1 期
PHASE 1/2 STUDY OF TAS-120 IN PATIENTS WITH ADVANCED SOLID TUMORS HARBORING FGF/FGFR ABERRATIONS
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 835
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
入选标准
- •1. Provide written informed consent.
- •2. Is = 18 years .
- •3. Has histologically or cytologically confirmed, locally advanced, metastatic cancer meeting the following criteria:
- •a. Phase 1 Expansion
- •I. Patient has failed all standard therapies or standard therapy does not exist or is not tolerated.
- •ii. Patient is eligible for 1 of the following enrollment groups, based on diagnosis, prior therapy, and FGF/FGFR aberrations as shown:
- •Group 1 (Enrollment Suspended as of Amendment 7): Patient has
- •intrahepatic or extrahepatic cholangiocarcinoma harboring FGFR2 gene
- •Group 2: Patient has intrahepatic or extrahepatic cholangiocarcinoma harboring FGFR2 gene fusions, and has not received or received less
- •than 1 cycle of prior chemotherapy (due to intolerance or patient refusal).
- •Group 3 (Enrollment Suspended as of Amendment 7): Patient has
- •intrahepatic or extrahepatic cholangiocarcinoma harboring FGFR2 gene
- •fusions and has received prior treatment with FGFR inhibitors.
- •Group 4 (Enrollment suspended as of Amendment 7): Patient has
- •intrahepatic or extrahepatic cholangiocarcinoma harboring FGFR
- •abnormalities other than FGFR2 gene fusions.
- •Group 5: Patient has a primary CNS tumor harboring FGFR gene fusion or
- •FGFR1 activating mutation and fulfills the criteria (i and ii).
- •Group 6 (Enrollment Suspended as of Amendment 7): Patient has
- •advanced urothelial carcinoma harboring FGFR3 fusions or FGFR3
- •activating mutations.
- •Group 7: Patient has any tumor type not included in one of the prior
- •groups, harboring FGFR2 amplification (no minimum number of copies).
- •Group 8 (Enrollment Suspended as of Amendment 7): Patient has any
- •tumor type not included in one of the prior groups, harboring FGFR gene
- •fusions or activating mutations.
- •i. Patient has histologically or cytologically confirmed, locally advanced,
- •metastatic, unresectable iCCA harboring FGFR2 gene fusions or other
- •FGFR2 rearrangements based on results from either of the following
- •a. Testing by Foundation Medicine:
- •i. As part of study pre-screening; or
- •ii. Previously tested by Foundation Medicine; in this case, tumor tissue
- •should be provided to Foundation Medicine if available.
- •b. Local laboratory testing using next generation sequencing [NGS],
- •fluorescence in situ hybridization [FISH], or other assays that can
- •determine FGFR2 gene fusions or other FGFR2 rearrangements on tumor
- •tissues or from ctDNA; patients enrolled on this basis must have
- •available tumor tissues from either archival samples or fresh tumor
- •biopsy submitted to Foundation Medicine for confirmation of FGFR2 gene
- •fusion or other FGFR2 rearrangements.
- •ii. Patient has been treated with at least one prior systemic gemcitabine
- •and platinum-based chemotherapy. Patients with p
排除标准
- •1. History and/or current evidence of clinically significant non-tumor
- •related alteration of calcium-phosphorus homeostasis.
- •2. History and/or current evidence of clinically significant ectopic
- •mineralization/calcification.
- •3. History and/or current evidence of clinically significant retinal
- •disorder confirmed by retinal examination.
- •4. History or current evidence of serious uncontrolled ventricular
- •arrhythmias
- •5. Fridericia's corrected QT interval (QTcF) > 470 ms on ECG conducted
- •during Screening.
- •6. Treatment with any of the following within the specified time frame
- •prior to the first dose of TAS-120:
- •a. Major surgery within the previous 4 weeks (the surgical incision
- •should be fully healed prior to the first dose of TAS 120).
- •b. Radiotherapy for extended field within 4 weeks or limited field
- •radiotherapy within 2 weeks.
- •c. Patients with locoregional therapy, e.g., transarterial
- •chemoembolization (TACE), selective internal radiotherapy (SIRT) or
- •ablation within 4 weeks.
- •d. Any noninvestigational anticancer therapy within 3 weeks or have
- •not recovered from side effects of such therapy prior to TAS 120
- •administration (mitomycin within prior 5 weeks).
- •Targeted therapy or immunotherapy within 3 weeks or within 5 halflives
- •(whichever is shorter)
- •e. Any investigational agent received within 5 half-lives of the drug or 4
- •weeks, whichever is shorter. Concurrent participation in an
- •observational study may be allowed after review by the Sponsor's
- •Medical Monitor.
- •f. Patients with prior FGFR-directed therapy.
- •7. A serious illness or medical condition(s) including, but not limited to,
- •the following:
- •a. Known brain metastasis (not including primary brain tumors) unless patient is clinically stable for = 1 month.
- •b. Known acute systemic infection.
- •c. Myocardial infarction, severe/unstable angina, symptomatic
- •congestive heart failure (New York Heart Association [NYHA] Class III
- •or IV (see Appendix D, New York Heart Association [NYHA]
- •Classification) within the previous 2 months; if > 2 months, cardiac
- •function must be within normal limits and the patient must be free of
- •cardiac-related symptoms.
- •d. Chronic nausea, vomiting, or diarrhea considered to be clinically
- •significant in the opinion of the investigator.
- •e. Congenital long QT syndrome, or any known history of torsade de
- •pointes, or family history of unexplained sudden death.
- •f. Other severe acute or chronic medical or psychiatric condition or
- •laboratory abnormality that in the judgment of the investigator would
- •make the patient inappropriate for entry into this study.
- •8. Patients with a history of another primary malignancy that is
- •currently clinically significant, and has potential for meta
研究者
相似试验
进行中（未招募）
1 期
A study of TAS-120 in patients with advanced cancer with genetic abnormalitiesAdvanced solid tumorsMedDRA version: 21.1Level: LLTClassification code 10065147Term: Malignant solid tumorSystem Organ Class: 100000004864EUCTR2013-004810-16-DETaiho Oncology Inc385
已完成
2 期
PHASE 1/2 STUDY OF TAS-120 IN PATIENTS WITH ADVANCED SOLID TUMORS HARBORING FGF/FGFR ABERRATIONSNL-OMON48846Taiho Oncology, Inc.20
进行中（未招募）
1 期
A study of TAS-120 in patients with advanced cancer with genetic abnormalitiesAdvanced solid tumorsMedDRA version: 21.1Level: LLTClassification code 10065147Term: Malignant solid tumorSystem Organ Class: 100000004864EUCTR2013-004810-16-PTTaiho Oncology Inc385
已完成
1 期
Phase I/II study of TAS-120JPRN-jRCT2080224117Taiho Pharmaceutical Co., Ltd.20
进行中（未招募）
1 期
A study of TAS-120 in patients with advanced cancer with genetic abnormalitiesEUCTR2013-004810-16-GBTaiho Oncology Inc385